Relative Supersaturation of 24-Hour Urine and Likelihood of Kidney Stones

Overview

Journal J Urol

Publisher Wolters Kluwer

Specialty Urology

Date 2017 Nov 15

PMID 29132983

Citations 25

Authors

Megan Prochaska

Eric Taylor

Pietro Manuel Ferraro

Gary Curhan

Affiliations

Soon will be listed here.

Abstract

Purpose: The relative supersaturation of calcium oxalate, calcium phosphate and uric acid is used clinically in kidney stone prevention. The magnitude of the association between relative supersaturation and stone risk requires further quantification.

Materials And Methods: We performed a cross-sectional study using 24-hour urine collections from the NHS (Nurses' Health Study) I and II, and HPFS (Health Professionals Follow-up Study) cohorts to quantify the association between the relative supersaturation of calcium oxalate, calcium phosphate and uric acid, and the likelihood of stone formation.

Results: The OR of being a stone former was 5.85 (95% CI 3.40-10.04) in NHS I, 6.38 (95% CI 3.72-11.0) in NHS II and 6.95 (95% CI 3.56-13.6) in HPFS for the highest category of calcium oxalate relative supersaturation compared with less than 1.0. The OR of being a stone former was 1.86 (95% CI 0.94-3.71) in NHS I, 4.37 (95% CI 2.68-7.10) in NHS II and 3.59 (95% CI 2.04-6.31) in HPFS for the highest category of calcium phosphate relative supersaturation compared with less than 1.0. For uric acid relative supersaturation the OR of being a stone former was 4.30 (95% CI 2.34-7.90) in NHS I and 2.74 (95% CI 1.71-4.40) in NHS II for the highest relative supersaturation category compared with less than 1.0. In HPFS the uric acid relative supersaturation was not significantly associated with the likelihood of stone formation.

Conclusions: The likelihood of being a stone former increases with higher relative supersaturation of calcium oxalate and calcium phosphate in men and women, and with higher relative supersaturation of uric acid in women.

Citing Articles

Empagliflozin in nondiabetic individuals with calcium and uric acid kidney stones: a randomized phase 2 trial.

Anderegg M, Schietzel S, Bargagli M, Bally L, Faller N, Moor M Nat Med. 2025; 31(1):286-293.

PMID: 39747681 PMC: 11750721. DOI: 10.1038/s41591-024-03330-x.

Metabolomic profiles and pathogenesis of nephrolithiasis.

Kowalczyk N, Prochaska M, Worcester E Curr Opin Nephrol Hypertens. 2023; 32(5):490-495.

PMID: 37530089 PMC: 10403267. DOI: 10.1097/MNH.0000000000000903.

Effect of two vitamin D repletion protocols on 24-h urine calcium in patients with recurrent calcium kidney stones and vitamin D deficiency: a randomized clinical trial.

Sardari Masihi L, Borumandnia N, Taheri M, Basiri A, Imani H, Jalali S Eur J Med Res. 2023; 28(1):246.

PMID: 37481570 PMC: 10362614. DOI: 10.1186/s40001-023-01226-z.

Calcium oxalate crystal-induced secretome derived from proximal tubular cells, not that from distal tubular cells, induces renal fibroblast activation.

Noonin C, Itsaranawet T, Thongboonkerd V Eur J Med Res. 2023; 28(1):150.

PMID: 37031165 PMC: 10082508. DOI: 10.1186/s40001-023-01109-3.

Characterization of Stone Events in Patients With Type 3 Primary Hyperoxaluria.

Arnous M, Vaughan L, Mehta R, Schulte P, Lieske J, Milliner D J Urol. 2023; 209(6):1141-1150.

PMID: 36888927 PMC: 11034812. DOI: 10.1097/JU.0000000000003400.

References

Lieske J, Rule A, Krambeck A, Williams J, Bergstralh E, Mehta R . Stone composition as a function of age and sex. Clin J Am Soc Nephrol. 2014; 9(12):2141-6. PMC: 4255407. DOI: 10.2215/CJN.05660614. View

Thun M, Schober S . Urolithiasis in Tennessee: an occupational window into a regional problem. Am J Public Health. 1991; 81(5):587-91. PMC: 1405067. DOI: 10.2105/ajph.81.5.587. View

Bergsland K, Coe F, Gillen D, Worcester E . A test of the hypothesis that the collecting duct calcium-sensing receptor limits rise of urine calcium molarity in hypercalciuric calcium kidney stone formers. Am J Physiol Renal Physiol. 2009; 297(4):F1017-23. PMC: 2775565. DOI: 10.1152/ajprenal.00223.2009. View

Coe F, Parks J, Asplin J . The pathogenesis and treatment of kidney stones. N Engl J Med. 1992; 327(16):1141-52. DOI: 10.1056/NEJM199210153271607. View

Werness P, Brown C, Smith L, Finlayson B . EQUIL2: a BASIC computer program for the calculation of urinary saturation. J Urol. 1985; 134(6):1242-4. DOI: 10.1016/s0022-5347(17)47703-2. View

Taylor E, Fung T, Curhan G . DASH-style diet associates with reduced risk for kidney stones. J Am Soc Nephrol. 2009; 20(10):2253-9. PMC: 2754098. DOI: 10.1681/ASN.2009030276. View

Lingeman J, Kahnoski R, Mardis H, Goldfarb D, Grasso M, Lacy S . Divergence between stone composition and urine supersaturation: clinical and laboratory implications. J Urol. 1999; 161(4):1077-81. View

Parks J, Coward M, Coe F . Correspondence between stone composition and urine supersaturation in nephrolithiasis. Kidney Int. 1997; 51(3):894-900. DOI: 10.1038/ki.1997.126. View

Pak C, Poindexter J, Adams-Huet B, Pearle M . Predictive value of kidney stone composition in the detection of metabolic abnormalities. Am J Med. 2003; 115(1):26-32. DOI: 10.1016/s0002-9343(03)00201-8. View

10.

HERRING L . Observations on the analysis of ten thousand urinary calculi. J Urol. 1962; 88:545-62. DOI: 10.1016/S0022-5347(17)64842-0. View

11.

Curhan G, Taylor E . 24-h uric acid excretion and the risk of kidney stones. Kidney Int. 2007; 73(4):489-96. DOI: 10.1038/sj.ki.5002708. View

12.

Singh P, Enders F, Vaughan L, Bergstralh E, Knoedler J, Krambeck A . Stone Composition Among First-Time Symptomatic Kidney Stone Formers in the Community. Mayo Clin Proc. 2015; 90(10):1356-65. PMC: 4593754. DOI: 10.1016/j.mayocp.2015.07.016. View

13.

Curhan G, Willett W, Speizer F, Stampfer M . Twenty-four-hour urine chemistries and the risk of kidney stones among women and men. Kidney Int. 2001; 59(6):2290-8. DOI: 10.1046/j.1523-1755.2001.00746.x. View